The acquisition could potentially expand Albemarle's portfolio and increase its market presence, which could have a positive impact on its stock. However, the deal is subject to several conditions including due diligence, regulatory approvals, and shareholder approval, which introduces uncertainties and risks. Therefore, the short-term impact on the stock is neutral.